Patents by Inventor Nadege A. Gaborit

Nadege A. Gaborit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EUKARYOTIC DNA REPLICATION ORIGINS, AND VECTOR CONTAINING THE SAME
    Publication number: 20240093182
    Abstract: A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.
    Type: Application
    Filed: September 6, 2021
    Publication date: March 21, 2024
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Marcel MECHALI, Ildem AKERMAN, Nadège GABORIT
  • Anti-HER3 antibodies and uses of same
    Patent number: 10526416
    Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HER3 and NRG-induced cancer cell migration and proliferation. Additionally clones NG83 and NG140 are provided which bind human HER-3 with a KD value of 10 nM or lower.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: January 7, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Nadège Gaborit, Moshit Lindzen
  • Neuregulin allosteric anti-HER3 antibody
    Patent number: 10196455
    Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: February 5, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
  • Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
    Patent number: 10011659
    Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 3, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Maicol Mancini, Nadège Gaborit
  • ANTI-HER3 ANTIBODIES AND USES OF SAME
    Publication number: 20170306049
    Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HERS and NRG-induced cancer cell migration and proliferation.
    Type: Application
    Filed: September 8, 2015
    Publication date: October 26, 2017
    Inventors: Yosef YARDEN, Nadège GABORIT, Moshit LINDZEN
  • Neuregulin Allosteric Anti-HER3 Antibody
    Publication number: 20160319033
    Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
    Type: Application
    Filed: November 7, 2013
    Publication date: November 3, 2016
    Inventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
  • COMPOSITIONS AND METHODS FOR TREATING CANCER RESISTANT TO A TYROSINE KINASE INHIBITOR (TKI)
    Publication number: 20160152712
    Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.
    Type: Application
    Filed: December 2, 2015
    Publication date: June 2, 2016
    Inventors: Yosef YARDEN, Maicol Mancini, Nadège Gaborit
  • Antibodies against HER3
    Patent number: 9346883
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 24, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Gamamabs Pharma SA
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • Anti-human HER3 antibodies and uses thereof
    Patent number: 9127065
    Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Val d'Aurelle—Paul Lamarque, Universite de Montpellier 1
    Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
  • ANTIBODIES AGAINST HER3
    Publication number: 20140141019
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 22, 2014
    Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • ANTI-HUMAN HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140112931
    Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
    Type: Application
    Filed: May 21, 2012
    Publication date: April 24, 2014
    Applicants: UNIVERSITE DE MONTPELLIER 1, CENTRE VAL D'AURELLE - PAUL LAMARQUE
    Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek